Current Opinion in Hematology最新文献_第2页

Posttransplant cyclophosphamide: a universal graft versus host disease prophylaxis. 移植后环磷酰胺：一种通用的移植物抗宿主疾病预防疗法。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-22 DOI: 10.1097/MOH.0000000000000840

Andrea Bacigalupo

{"title":"Posttransplant cyclophosphamide: a universal graft versus host disease prophylaxis.","authors":"Andrea Bacigalupo","doi":"10.1097/MOH.0000000000000840","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000840","url":null,"abstract":"Purpose of the review: The purpose of this review is to outline current graft versus host disease (GvHD) prophylaxis, in the era of posttransplant cyclophosphamide (PTCY), in patients with malignant and nonmalignant hematologic disorders. The original combination of PTCY with a calcineurin inhibitor (CNI) and mycophenolate (MMF), reported from the Johns Hopkins University in Baltimore, was designed for patients receiving a graft from a donor mismatched at one haplotype, so called haploidentical donor (HAPLO). In the past decade, PTCY has been widely used in HAPLO transplants worldwide, confirming the amazing efficacy of PTCY in preventing GvHD in mismatched grafts.Recent findings: More recently, PTCY is being tested also in grafts from human leukocyte antigen (HLA) identical related or unrelated donors. In the present review we will also answer several open questions, such as: PTCY and cardiac toxicity; PTCY dose; PTCY timing; PTCY and antithymocyte globulin (ATG); engraftment kinetics; infections; PTCY and leukemia relapse; PTCY and HLA identical grafts.Summary: PTCY is currently one of the most effective measures to prevent GvHD, and can be customized in different transplant platforms, together with other immunosuppressive agents. There is place for improvement, and several possible modifications of PTCY dose and schedule can be tested in prospective trials.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683398","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Unraveling lipid metabolism for acute myeloid leukemia therapy. 揭示急性髓性白血病治疗中的脂质代谢。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-19 DOI: 10.1097/MOH.0000000000000853

Cristiana O'Brien, Courtney L Jones

{"title":"Unraveling lipid metabolism for acute myeloid leukemia therapy.","authors":"Cristiana O'Brien, Courtney L Jones","doi":"10.1097/MOH.0000000000000853","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000853","url":null,"abstract":"Purpose of review: The aim of this review is to highlight the importance of lipids' intricate and interwoven role in mediating diverse acute myeloid leukemia (AML) processes, as well as potentially novel lipid targeting strategies. This review will focus on new studies of lipid metabolism in human leukemia, particularly highlighting work in leukemic stem cells (LSCs), where lipids were assessed directly as a metabolite.Recent findings: Lipid metabolism is essential to support LSC function and AML survival through diverse mechanisms including supporting energy production, membrane composition, signaling pathways, and ferroptosis. Recent work has highlighted the role of lipid rewiring in metabolic plasticity which can underlie therapy response, the impact of cellular and genetic heterogeneity in AML on lipid metabolism, and the discovery of noncanonical roles of lipid related proteins in AML.Summary: Recent findings around lipid metabolism clearly demonstrates their importance to our understanding and therapeutic targeting of AML. We have only begun to unravel the regulation and utilization of lipids in this disease. Further, understanding the layered dynamics of lipid homeostasis could provide novel opportunities to target lipid metabolism in AML and LSCs with the potential of improving outcomes for patients with AML.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142711700","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding. 骨髓性肿瘤中的胚系 DDX41 基因突变：目前的临床和分子认识。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-15 DOI: 10.1097/MOH.0000000000000854

Junichiro Kida, Timothy M Chlon

{"title":"Germline DDX41 mutations in myeloid neoplasms: the current clinical and molecular understanding.","authors":"Junichiro Kida, Timothy M Chlon","doi":"10.1097/MOH.0000000000000854","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000854","url":null,"abstract":"Purpose of review: DDX41 mutations are the most common cause of germline predisposition to adult-onset myeloid neoplasms. The unique mutational landscape and clinical features indicate a distinct molecular pathogenesis, but the precise mechanism by which DDX41 mutations cause disease is poorly understood, owing to the multitude of DDX41 functions. In this review, we will update DDX41's known functions, present unique clinical features and treatment considerations, and summarize the current understanding of the molecular pathogenesis of the disease.Recent findings: Large cohort studies have revealed that germline DDX41 variants are heterozygous and predominantly loss-of-function. Acquired mutation of the contralateral DDX41 allele, typically R525H, is present in more than half of patients at disease onset, which occurs after age 50. DDX41 is essential for hematopoiesis and has versatile functions in RNA metabolism and innate immune sensing. Experimental models have suggested that innate immune activation downstream of defects in R-loop resolution and ribosome biogenesis plays a key role in the pathogenesis.Summary: While intensive investigations unveiled a strong genotype-phenotype relationship, the optimal therapeutic approach and long-term outcome are undefined. There is an urgent need to scrutinize the patients at single cell and multiomics level and to advance experimental animal and human models to fully elucidate the molecular pathogenesis.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":""},"PeriodicalIF":3.1,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142677807","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Novel neutrophil biology insights underlying atypical chemokine receptor-1/Duffy antigen receptor of chemokines-associated neutropenia. 非典型趋化因子受体-1/达菲抗原受体与中性粒细胞减少症相关的中性粒细胞生物学新见解。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-24 DOI: 10.1097/MOH.0000000000000834

Johnson M Liu, Hongbo R Luo

{"title":"Novel neutrophil biology insights underlying atypical chemokine receptor-1/Duffy antigen receptor of chemokines-associated neutropenia.","authors":"Johnson M Liu, Hongbo R Luo","doi":"10.1097/MOH.0000000000000834","DOIUrl":"10.1097/MOH.0000000000000834","url":null,"abstract":"Purpose of review: Atypical chemokine receptor-1 (ACKR1)/Duffy antigen receptor of chemokines (DARC)-associated neutropenia (ADAN; OMIM 611862), previously named benign ethnic neutropenia, and present in two-thirds of individuals identifying as Black in the USA, is associated with mild to moderate decreases in peripheral neutrophil counts that nevertheless do not lead to increased infections. Consequently, recent initiatives have sought to establish normal neutrophil count reference ranges for ADAN, considering it a normal variant rather than a clinical disorder requiring medical intervention.Recent findings: A limited number of studies elucidating the mechanism of neutropenia in ADAN has suggested that neutrophils may redistribute from peripheral blood to the tissues including the spleen: this might explain why ADAN is not associated with increased risks of infection since the total number of neutrophils in the body remains normal. In this review, we critically examine the research underlying the molecular basis of ADAN.Summary: Insights into the biology of neutrophils and their trafficking may inform the clinical interpretation of neutropenia in ADAN. The bulk of research suggests that ADAN does not lead to a diminished host defense as do other forms of neutropenia. However, ADAN may lead to increased proinflammatory signaling, with possible implications for senescence of the immune system and predisposition to autoimmunity and cancer.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"302-306"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426986/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141753431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

New insights of glycoprotein Ib-IX-V complex organization and glycoprotein Ibα in platelet biogenesis. 糖蛋白 Ib-IX-V 复合物组织和糖蛋白 Ibα 在血小板生物生成过程中的新见解。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-16 DOI: 10.1097/MOH.0000000000000832

Lulu Huang, Bojing Shao

{"title":"New insights of glycoprotein Ib-IX-V complex organization and glycoprotein Ibα in platelet biogenesis.","authors":"Lulu Huang, Bojing Shao","doi":"10.1097/MOH.0000000000000832","DOIUrl":"10.1097/MOH.0000000000000832","url":null,"abstract":"Purpose of review: Glycoprotein (GP) Ib-IX-V, a platelet surface receptor that plays a critical role in platelet adhesion and platelet-mediated immune responses, consists of GPIbα, GPIbβ, GPIX, and GPV in a stoichiometry of 2 : 4 : 2 : 1. Forming a complex is essential for GPIb-IX-V to function. GPIb-IX-V also plays an important role in platelet biogenesis by regulating the number and size of platelets. Yet how GPIb-IX-V regulates platelet biogenesis remains elusive. This review will summarize recent findings in the complex organization of GPIb-IX-V and its role in platelet biogenesis.Recent findings: Proteomics studies suggest that GPIbα, GPIbβ, GPIX, and GPV form the complex in a ratio of 1 : 2 : 1 : 1, which is supported by analysis of molecular weight of GPIb-IX-V and GPIb-IX and the structure of entire GPIb-IX-V. To activate platelets, GPIbα requires binding of CLEC-2 to trigger signals. Furthermore, disrupting the GPIbα anchorage to filamin A causes defects in platelet budding away from proplatelets leading to giant platelets and a low platelet count.Summary: New studies challenge the traditional model for the organization of GPIb-IX-V as a complex and indicate the role of GPIb-IX-V in platelet production. Those studies provide insights for GPIb-IX-V in the regulation of platelet activation and platelet biogenesis.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"294-301"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prophylactic red cell transfusions for sickle cell disease pregnancy: increased use of therapy could transform outcomes. 镰状细胞病妊娠的预防性红细胞输注：增加治疗的使用可改变预后。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-22 DOI: 10.1097/MOH.0000000000000837

Sheinei Alan, Deva Sharma, Lydia H Pecker

{"title":"Prophylactic red cell transfusions for sickle cell disease pregnancy: increased use of therapy could transform outcomes.","authors":"Sheinei Alan, Deva Sharma, Lydia H Pecker","doi":"10.1097/MOH.0000000000000837","DOIUrl":"10.1097/MOH.0000000000000837","url":null,"abstract":"Purpose of review: Pregnancy for people with sickle cell disease (SCD) is high risk with persistently high rates of severe maternal and fetal mortality and morbidity. Transfusion therapy is the best-studied treatment for SCD in pregnancy; hydroxyurea is not usually used because of teratogenicity concerns. In high-resource settings, red cell transfusions are likely underutilized, while in low-resource settings, they may be altogether unavailable.Recent findings: A randomized controlled trial and meta-analysis, two of the strongest forms of clinical research, show transfusion significantly reduces maternal and fetal death, painful crisis, thrombosis, and acute respiratory failure. Downstream benefits of treatment are less well measured and may include improving maternal anemia, reducing opioid exposure, and avoiding hospitalization, which presents risk for additional complications. Alloimmunization is a particular transfusion risk in SCD. However, many strategies can mitigate this risk. Accordingly, the American Society of Hematology classifies chronic transfusion in pregnancy as low risk.Summary: Given the low risk classification, lack of alternative therapies, dismal, stagnant pregnancy outcomes and the potential for profound treatment benefit, wider use of chronic transfusion therapy for SCD pregnancy is likely indicated. This review discusses the benefits and potential risks of prophylactic transfusions for SCD pregnancy. Use of chronic transfusions during pregnancy is indicated to help urgently transform outcomes.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"285-293"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427169/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142037833","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Heme- and iron-activated macrophages in sickle cell disease: an updated perspective. 镰状细胞病中的血红素和铁激活巨噬细胞：最新观点。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-16 DOI: 10.1097/MOH.0000000000000836

Shobana Navaneethabalakrishnan, Xiuli An, Francesca Vinchi

{"title":"Heme- and iron-activated macrophages in sickle cell disease: an updated perspective.","authors":"Shobana Navaneethabalakrishnan, Xiuli An, Francesca Vinchi","doi":"10.1097/MOH.0000000000000836","DOIUrl":"10.1097/MOH.0000000000000836","url":null,"abstract":"Purpose of review: Sickle cell disease (SCD) is a hereditary blood disorder due to a single-point mutation in the β-globin gene. The ensuing hemoglobin has the tendency to polymerize upon deoxygenation, leading to the typical sickle shape of red blood cells. While the primary pathology of sickle cell disease is a direct consequence of altered red blood cells, emerging evidence highlights the central role of macrophages in mediating hemoglobin scavenging, perpetuating oxidative stress and inflammation, and causing endothelial dysfunction and tissue remodeling.Recent findings: Recent research uncovered the impact of heme and iron overload on macrophage polarization and functions in sickle cell disease, and its implication for chronic inflammation and tissue damage in vital organs such as the liver, spleen, lungs and kidneys. By providing a thorough understanding of the dynamic interactions between macrophages and various cellular components within the sickle cell disease milieu, these studies have laid the foundation for the identification of macrophage-related cellular and molecular mechanisms potentially targetable for therapeutic purposes to attenuate sickle complications.Summary: This review provides a current update about recent discoveries on heme/iron-activated macrophages in SCD, shedding light on their critical role in disease pathophysiology. Ultimately, it proposes avenues for future research aimed at addressing the relevance of these cells for other sickle complications and at targeting them to mitigate disease morbidity and improve patient outcomes.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"275-284"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11427154/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Viral infection after hematopoietic stem cell transplantation. 造血干细胞移植后的病毒感染。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-08-12 DOI: 10.1097/MOH.0000000000000833

Per Ljungman

{"title":"Viral infection after hematopoietic stem cell transplantation.","authors":"Per Ljungman","doi":"10.1097/MOH.0000000000000833","DOIUrl":"https://doi.org/10.1097/MOH.0000000000000833","url":null,"abstract":"Purpose of review: Viral infections are important complications after allogeneic hematopoietic stem cell transplantation. New infections develop such as SARS-CoV-2 with the potential for severe consequences. In this review, newly published information regarding management of viral infections is discussed.Recent findings: Letermovir and maribavir are antiviral agents that have positively impacted the management of cytomegalovirus infections. These should today be included in treatment algorithms. The first antiviral cellular therapy for anti-CD20 refractory EBV-associated lymphoproliferative disease is now licensed and available. Vaccination as well as introduction of antiviral agents, mAbs and possibly the development of different viral strains have reduced mortality in COVID-19 in this patient population. Well designed studies have shown the improved immunogenicity of high-dose influenza vaccines. There is still an unmet medical need for patients infected with human metapneumovirus and parainfluenza viruses.Summary: Although improvements in patient management for several important posttransplantation viral infections have been reported, an unmet medical need still exists for other viruses occurring in this high-risk population.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":"31 6","pages":"270-274"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142332724","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-19 DOI: 10.1097/MOH.0000000000000835

Alexander H Schmidt

{"title":"Unrelated hematopoietic stem cell donor registries: present reality and future prospects.","authors":"Alexander H Schmidt","doi":"10.1097/MOH.0000000000000835","DOIUrl":"10.1097/MOH.0000000000000835","url":null,"abstract":"Purpose of review: Stem cell donor registries play an important role in providing stem cell products from unrelated donors to patients with severe blood diseases. In this review, important aspects of donor registry work, current challenges and possible future developments are discussed.Recent findings: The current growth in global unrelated stem cell donations is in line with the long-term trend, indicating that donor registries have overcome the COVID-19 pandemic. A key challenge for donor registries is the recruitment of donors from disadvantaged populations to create greater equity in access to unrelated stem cell transplantation. In addition, recruiting young donors and increasing the availability of donors who are already registered are important goals. In recent years, numerous studies have looked at the context of these themes and the development of possible solutions.Summary: The international community of donor registries, together with the World Marrow Donor Association, has helped many patients in need of a stem cell transplant over the past decades and is, therefore, a bright example of international collaboration for a good cause. It is currently addressing a number of challenges to effectively help as many patients as possible from various populations also in the future.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"251-260"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11426981/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Donor selection in allogeneic stem cell transplantation. 异体干细胞移植中的供体选择。

IF 3.1 3区医学

Current Opinion in Hematology Pub Date : 2024-11-01 Epub Date: 2024-07-15 DOI: 10.1097/MOH.0000000000000831

Francisco Barriga, Alberto Cardoso Martins Lima

{"title":"Donor selection in allogeneic stem cell transplantation.","authors":"Francisco Barriga, Alberto Cardoso Martins Lima","doi":"10.1097/MOH.0000000000000831","DOIUrl":"10.1097/MOH.0000000000000831","url":null,"abstract":"Purpose of review: Recent progress in human leukocyte antigen (HLA) characterization, increased accrual of unrelated donors and cord blood units, and a new platform for haploidentical transplantation have resulted in the widespread availability of donors for allogeneic hematopoietic stem cell transplantation.Recent findings: Advances in HLA typing have identified an increasing number of loci and alleles that are crucial for successful transplantation. Newer HLA A, B, C, DRB1, and DQB1 alleles, DPB1 mismatches, and HLA B leader sequence matching are incorporated into donor selection algorithms. Donor selection is highly relevant because of recently published conflicting studies using different donor types. These studies are largely retrospective and compare patients with different diseases and stages, conditioning regimens, graft versus host disease (GVHD) prophylaxis, and time periods. A broad consensus indicates that the best donor is an available matched sibling, followed by a matched unrelated donor, and then alternative donors such as haploidentical, mismatched unrelated, and cord blood units. This consensus is being challenged by other factors, such as donor age, patient condition, urgency of transplantation, and costs involved.Summary: In this review, we will analyze the unique characteristics of each donor type, the HLA and non HLA factors that affect donor choices, and the outstanding comparative outcome studies of different donor usage in hematologic malignancies.","PeriodicalId":55196,"journal":{"name":"Current Opinion in Hematology","volume":" ","pages":"261-269"},"PeriodicalIF":3.1,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141762776","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0